Rezvoglar™ (insulin glargine-aglr) injection

3 mL (100 units/mL)

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the guidance for the administration of Rezvoglar™ (insulin glargine‑aglr)?

Proper administration and dosing of Rezvoglar require adherence to specific instructions.

US_cFAQ_REZ024_ADMINISTRATION
cFAQ
cFAQ
US_cFAQ_REZ024_ADMINISTRATION
en-US

Administration Instructions

Always check insulin labels before administration.1

Instruct patients on proper use and injection technique before initiating Rezvoglar™ (insulin glargine-aglr) 100 units/mL.1

Visually inspect the Rezvoglar KwikPen® for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.1

Administer Rezvoglar subcutaneously into the abdominal area, thigh, or deltoid.1

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.1

Do not dilute or mix Rezvoglar with any other insulin or solution.1

Do not administer Rezvoglar intravenously or via an insulin pump.1

Dosing Instructions

In patients with type 1 diabetes, use Rezvoglar concomitantly with short-acting insulin.1

Inject Rezvoglar subcutaneously once daily at any time of day but at the same time every day.1

Individualize and adjust the dosage of Rezvoglar based on the individual’s

  • metabolic needs
  • blood glucose monitoring results
  • glycemic control goal
  • type of diabetes, and
  • prior insulin use.1

Perform dosage adjustments of Rezvoglar under medical supervision and with appropriate glucose monitoring. Dosage adjustments may be needed with

  • changes in physical activity
  • changes in meal patterns, such as with macronutrient content or timing of food intake
  • episodes of acute illness, or
  • changes in renal or hepatic function.1

Reference

1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: April 04, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical